Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: To evaluate the efficacy of the TINI laser device, a photobiomodulation (PBM) therapy, for managing chronic high-frequency tinnitus in patients with unilateral or bilateral tinnitus.
Methods: A randomised, single-blind, placebo-controlled clinical trial was conducted with 38 participants. Subjects were divided into three groups: The TINI 1 group received eight active laser treatments over 4 weeks, the TINI 2 group received four active treatments followed by four sham treatments, and the control group received only sham treatments. The Tinnitus Handicap Inventory (THI), Tinnitus Functional Index (TFI) and Tinnitus Magnitude Index (TMI) were used to assess tinnitus-related outcomes. Psychological assessments were also conducted to measure levels of depression, stress and anxiety.
Results: Significant improvements were observed in the emotional subscale of the THI, and in the loudness and perception scores of the TMI in the TINI 1 group. The TINI 2 group showed significant reductions in TFI and TMI scores following active treatments, although these effects diminished after sham treatments. No placebo effects were observed except for TFI scores in the control group.
Conclusion: The study indicates that intermittent PBM therapy using the TINI laser may be effective in managing chronic tinnitus. Further research is necessary to explore long-term efficacy and safety.
Trial Registration: cris.nih.go.kr identifier: PRE20240926-004.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/coa.14291 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chlorthalidone In Vitro Metabolite Identification for Documenting Exposure in Doping.
J Anal Toxicol
July 2025
Unit of Forensic Toxicology, Section of Legal Medicine, Department of Biomedical Sciences and Public Health-Marche Polytechnic University, Ancona, Italy.
Diuretics are commonly used in doping because they can conceal the presence of performance-enhancing substances in an athlete's urine through dilution and promote rapid weight loss. As a result, these substances are prohibited in sports by the World Anti-Doping Agency (WADA) under the S5 category ("Diuretics and Masking Agents"). Chlorthalidone, a thiazide-like diuretic, is medically used as an antihypertensive agent and is prescribed for conditions such as heart failure and liver cirrhosis.
View Article and Find Full Text PDFMyosin-ATPase inhibitor in real-world patients with obstructive HCM: a report by the Cardiomyopathies and Pericardial Diseases WG of the Italian Society of Cardiology.
J Cardiovasc Med (Hagerstown)
July 2025
Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine.
Introduction: Approximately two-thirds of patients suffering from hypertrophic cardiomyopathy present with an obstructive (HOCM) physiology. For years, medical therapy has been limited to beta blockers, verapamil and/or disopyramide. Recently, a novel class of drugs, the allosteric inhibitors of the cardiac-specific myosin head adenosine triphosphatase (ATPase), have been demonstrated to be effective in relieving the dynamic obstruction and related clinical condition.
View Article and Find Full Text PDFHigh-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy.
Circ Heart Fail
August 2025
Amyloidosis Research and Treatment Center (R.M., S.P., G.P., P.M.), Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Background: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. The aims of this study were: first, to assess the prognostic performance of hs-cTnI measured with different assays in patients with wild-type transthyretin amyloid cardiomyopathy and, second, to identify assay-specific hs-cTnI thresholds for prognosis that could be integrated into staging systems for risk stratification.
Methods: Observational multicenter study of stable wild-type transthyretin amyloid cardiomyopathy patients from different cohorts using the Abbott Architect Stat hs-cTnI assay and the Beckman Coulter Access hs-cTnI assay (testing cohorts) and the Siemens Centaur XPT hs-cTnI assay (validation cohort).
Critical approach to the 2023 European Society of Cardiology guidelines on cardiomyopathies: a document by the Working Group on Myocardial and Pericardial Diseases of the Italian Society of Cardiology.
J Cardiovasc Med (Hagerstown)
March 2025
Department of Medicine (DMED), University of Udine.
Last year, the European Society of Cardiology (ESC) published the first guidelines to comprehensively address the management of cardiomyopathies. This document by the Working Group on Myocardial and Pericardial Diseases of the Italian Society of Cardiology aims at highlighting the most relevant messages and novelties introduced by these guidelines for the management of patients affected by cardiomyopathies. Five main messages are summarized: the key role of the phenotype, the new classification of cardiomyopathies provided in the ESC guidelines, the importance given to new techniques such as cardiac magnetic resonance (CMR) and genetic testing, the newly provided recommendations given on sport activities and finally how the importance of follow-up evaluations is highlighted.
View Article and Find Full Text PDFEvaluation of the Photobiomodulation Treatment With the TINI Laser Device for Managing Chronic High-Frequency Tinnitus: A Randomised Controlled Trial.
Clin Otolaryngol
May 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Dankook University College of Medicine, Dankook University Hospital, Cheonan-si, Chungcheongnam-do, Republic of Korea.
Introduction: To evaluate the efficacy of the TINI laser device, a photobiomodulation (PBM) therapy, for managing chronic high-frequency tinnitus in patients with unilateral or bilateral tinnitus.
Methods: A randomised, single-blind, placebo-controlled clinical trial was conducted with 38 participants. Subjects were divided into three groups: The TINI 1 group received eight active laser treatments over 4 weeks, the TINI 2 group received four active treatments followed by four sham treatments, and the control group received only sham treatments.